Press "Enter" to skip to content

Lilly’s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

The new migraine drugs are the first designed to prevent the debilitating headaches. Drugmakers predicted that millions of patients could benefit and Wall Street analysts forecast nearly $4 billion in sales in the coming years.

Original source:

Also Read:   Government prohibits distribution, sale of Buclizine as 'appetite stimulant'